US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

8.22

-1.0000-10.85%

Post-market: 8.350.1300+1.58%18:04 EST

Volume:136.69K

Turnover:1.17M

Market Cap:76.06M

PE:-2.86

High:9.47

Open:9.32

Low:8.02

Close:9.22

52wk High:16.94

52wk Low:1.80

Shares:9.25M

Float Shares:4.93M

Volume Ratio:1.98

T/O Rate:2.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8732

EPS(LYR):-2.0179

ROE:-71.42%

ROA:-42.78%

PB:2.92

PE(LYR):-4.07

Loading ...

Overview Company News Filings

HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11

MT Newswires Live

CervoMed upgraded to Buy from Neutral at H.C. Wainwright

CervoMed Inc : H.c. Wainwright Raises Target Price to $25 From $11

THOMSON REUTERS

CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating

CervoMed Is Maintained at Buy by D. Boral Capital

CervoMed Unveils Presentation Highlighting Neflamapimod’s Phase 2b Success and Plans for Pivotal Dementia Trial

CervoMed Inc: Advancing Preparations for Global Pivotal Trial Initiation in Second Half of 2026

THOMSON REUTERS

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

CervoMed appoints Quigley to board of directors

Press Release: CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

CervoMed Showcases Neflamapimod’s Phase 2b Progress for Dementia with Lewy Bodies

CervoMed Releases Investor Presentation on Website

CervoMed to Present at the Emerging Growth Conference

CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating

CervoMed Unveils Promising Phase 2b Trial Results

CervoMed Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial and Business Officer Matthew Winton

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy

CervoMed’s Strategic Advancements in Clinical Trials Justify Buy Rating

CervoMed Inc Shares Rise 3.5% After Dementia Drug Shows Promise in Mid-Stage Study

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CRVO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":8.22,"timestamp":1764709200000,"preClose":9.22,"halted":0,"volume":136690,"hourTrading":{"tag":"盘后","latestPrice":8.35,"preClose":8.22,"latestTime":"18:04 EST","volume":1625,"amount":13507.139750000002,"timestamp":1764716666887},"delay":0,"floatShares":4934300,"shares":9252719,"eps":-2.873156,"marketStatus":"Post-Mkt","change":-1,"latestTime":"12-02 18:11:52 EST","open":9.32,"high":9.465,"low":8.0217,"amount":1170499.98068,"amplitude":0.15654,"askPrice":8.5,"askSize":100,"bidPrice":8.06,"bidSize":30,"shortable":0,"etf":0,"ttmEps":-2.873156,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":9.22,"preHourTrading":{"tag":"盘前","latestPrice":8.8777,"preClose":9.22,"latestTime":"09:02 EST","volume":4452,"amount":41298.804372,"timestamp":1764684166460},"postHourTrading":{"tag":"盘后","latestPrice":8.35,"preClose":8.22,"latestTime":"18:04 EST","volume":1625,"amount":13507.139750000002,"timestamp":1764716666887},"volumeRatio":1.975894},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":4934300,"roa":"-42.78%","roe":"-71.42%","lyrEps":-2.017884,"volumeRatio":1.975894,"shares":9252719,"dividePrice":0,"high":9.465,"amplitude":0.15654,"preClose":9.22,"low":8.0217,"week52Low":1.8,"pbRate":"2.92","psRate":"12.35","week52High":16.94,"institutionHeld":0,"latestPrice":8.22,"committee":-0.538462,"eps":-2.873156,"divideRate":0,"volume":136690,"delay":0,"ttmEps":-2.873156,"open":9.32,"prevYearClose":2.34,"prevWeekClose":9.94,"prevMonthClose":9.94,"prevQuarterClose":8.09,"fiveDayClose":9.27,"twentyDayClose":7.02,"sixtyDayClose":9.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"CRVO","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2025-05-12","symbol":"CRVO","fiscalQuarterEnding":"2025/03","expectedEps":-0.6,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.56},{"market":"US","date":"2025-03-17","symbol":"CRVO","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"CRVO","fiscalQuarterEnding":"2024/09","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":7,"updateTime":1762578000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2025-12-01","current":-2.885329,"percent":0.743316,"low":-119.682483,"twenty":-38.592039,"median":-6.928661,"eighty":-3.315314,"high":-1.31262,"avg":-21.615999,"sd":24.864836,"marketCap":91972026},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-31","current":-2.909391,"twenty":-38.804612,"median":-7.450846,"eighty":-3.374238,"marketCap":65786832},{"date":"2025-11-07","current":-2.983046,"twenty":-38.663931,"median":-7.254628,"eighty":-3.361323,"marketCap":67452321},{"date":"2025-11-14","current":-2.621936,"twenty":-38.6419,"median":-7.20399,"eighty":-3.333221,"marketCap":67082212},{"date":"2025-11-21","current":-3.258434,"twenty":-38.625998,"median":-7.137979,"eighty":-3.315314,"marketCap":83366998},{"date":"2025-11-28","current":-3.594765,"twenty":-38.625995,"median":-6.963795,"eighty":-3.314496,"marketCap":91972026},{"date":"2025-12-01","current":-3.594765,"twenty":-38.592039,"median":-6.928661,"eighty":-3.315314,"marketCap":91972026}],"updateTime":1764696184687},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581724728","title":"HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724728?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:29","pubTimestamp":1762345772,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of Buy and mean price target of $20.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2581725952","title":"CervoMed upgraded to Buy from Neutral at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2581725952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581725952?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:15","pubTimestamp":1762341332,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju upgraded CervoMed (CRVO) to Buy from Neutral with a $25 price target after the company received written ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2581230577","title":"CervoMed Inc : H.c. Wainwright Raises Target Price to $25 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2581230577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581230577?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:12","pubTimestamp":1762341156,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nAZN4QKGTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2581757304","title":"CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581757304","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581757304?lang=en_us&edition=fundamental","pubTime":"2025-11-05 01:55","pubTimestamp":1762278911,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on CervoMed. The associated price target remains the same with $20.00. Soumit R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-progress-for-neflamapimod-boosts-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-progress-for-neflamapimod-boosts-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","CRVO"],"gpt_icon":0},{"id":"2580737671","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737671?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:52","pubTimestamp":1762264320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 08:52 ET (13:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2580732078","title":"CervoMed Unveils Presentation Highlighting Neflamapimod’s Phase 2b Success and Plans for Pivotal Dementia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580732078","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580732078?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:40","pubTimestamp":1762263606,"startTime":"0","endTime":"0","summary":"CervoMed Inc. has provided an update on the development of neflamapimod, an investigational oral therapy targeting dementia with Lewy bodies . The company reported that neflamapimod achieved clinical proof-of-concept in a Phase 2b study, and alignment has been reached with the FDA to proceed to a pivotal 32-week Phase 3 trial involving approximately 300 patients with DLB. Results from the AscenD-LB Phase 2a trial indicated significant improvements in dementia severity and gait, as well as reductions in biomarkers associated with neurodegeneration. Preclinical studies showed reversal of neurodegenerative processes in relevant animal models. The safety profile of neflamapimod has been well characterized in over 700 volunteers and patients. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL33ZC75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2580733092","title":"CervoMed Inc: Advancing Preparations for Global Pivotal Trial Initiation in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2580733092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580733092?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG0Q0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2580588735","title":"CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2580588735","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580588735?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257600,"startTime":"0","endTime":"0","summary":"FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180155/0/en/CervoMed-Announces-Alignment-with-FDA-on-Registration-Path-for-Neflamapimod-in-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0240878834.USD","LU0345774631.USD","LU0240877869.USD","BK4139","AD","CRVO","BK4132","LU0345774391.USD","BK4097","LU0205194284.USD","LU0205193047.USD","LU0348723411.USD","DLB"],"gpt_icon":0},{"id":"2578495458","title":"CervoMed appoints Quigley to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578495458","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578495458?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:31","pubTimestamp":1761654711,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced the appointment of David Quigley to its Board of Directors. Quigley is a seasoned executive and former Senior Partner at ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-quigley-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-appoints-quigley-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2578959367","title":"Press Release: CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959367","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959367?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652800,"startTime":"0","endTime":"0","summary":"Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm. Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning. \"It is a pleasure to welcome David to our Board,\" said Joshua Boger, Ph.D., Chair of the CervoMed Board of Directors and founder of Vertex Pharmaceuticals. \"His strategic insight and commercial acumen are ideally suited to support CervoMed's mission as we advance neflamapimod toward transformative milestones. We look forward to leveraging his extensive business strategy and financial insights, as well as his broad network of relationships in the pharmaceutical and private equity industries, to drive progress for patients and value for our stockholders.\". DLB is the second most common progressive dementia after Alzheimer's di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","CRVO","LU0240877869.USD","BK4097","LU0205194284.USD","BK4139","LU0345774631.USD","LU0205193047.USD","DLB","LU0345774391.USD","LU0240878834.USD"],"gpt_icon":0},{"id":"2578629101","title":"CervoMed Showcases Neflamapimod’s Phase 2b Progress for Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2578629101","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578629101?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:06","pubTimestamp":1761584791,"startTime":"0","endTime":"0","summary":"Cervomed Inc. has announced that neflamapimod, its investigational oral therapy, has achieved Phase 2b clinical proof-of-concept and is now progressing into a 24-week pivotal study for dementia with Lewy bodies . The company highlights that DLB represents a significant and underserved global market. Preclinical studies demonstrated that neflamapimod reversed neurodegenerative processes in animal models, including improvements in cholinergic neuron function and behavioral outcomes. In the 16-week, placebo-controlled Phase 2a clinical trial  involving 91 patients with DLB, neflamapimod significantly improved dementia severity and gait compared to placebo and reduced plasma biomarkers associated with neurodegeneration. The therapy showed a well-defined safety profile, with clinical safety data from over 700 volunteers and patients. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL1y4LNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2577331110","title":"CervoMed Releases Investor Presentation on Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2577331110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577331110?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:36","pubTimestamp":1761165384,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an announcement. CervoMed Inc. has made available a presentation on its website, detailing its business, clinical s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-investor-presentation-on-website?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-investor-presentation-on-website?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2576851054","title":"CervoMed to Present at the Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851054","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851054?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961600,"startTime":"0","endTime":"0","summary":"BOSTON, Oct.  20, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169277/0/en/CervoMed-to-Present-at-the-Emerging-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2576037743","title":"CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2576037743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576037743?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:15","pubTimestamp":1760703359,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on CervoMed, retaining the price target of $20.00. Soumit Roy has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-plans-and-financial-outlook-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-plans-and-financial-outlook-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2574970677","title":"CervoMed Unveils Promising Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2574970677","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574970677?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:59","pubTimestamp":1759957196,"startTime":"0","endTime":"0","summary":"The latest update is out from CervoMed ( ($CRVO) ). On October 8, 2025, CervoMed Inc. announced new data from its Phase 2b RewinD-LB trial, highlig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-unveils-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-unveils-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2574972322","title":"CervoMed Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial and Business Officer Matthew Winton","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972322","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574972322?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:07","pubTimestamp":1759954047,"startTime":"0","endTime":"0","summary":"Cervomed Inc. has filed an initial statement of beneficial ownership  with the SEC. The filing lists Matthew Winton as the beneficial owner, who serves as the company's Chief Commercial and Business Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDLbbk7BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2574470975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574470975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574470975?lang=en_us&edition=fundamental","pubTime":"2025-10-09 01:39","pubTimestamp":1759945145,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best BuyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL6N3VP0FJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMI","LU1559883803.SGD","URI","LU1917777945.USD","HOWL","PEP","PSX","CRVO","SCCO","SLB","CTVA","DDOG","LU2023250843.SGD","JEF","CDE","DAL","LU0130102774.USD","LU0251142724.SGD","LU0203347892.USD","LYV","BLD","HOTH","BK4548","NEXT","ZBIO","CFLT","BK4022","CHRW","HL","ARCB","ATON","NEM","F","CVS","BBY","EFX","FDX","WERN","ELF","SMTC","CAT","FRPT"],"gpt_icon":1},{"id":"2574978999","title":"CervoMed’s Strategic Advancements in Clinical Trials Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574978999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574978999?lang=en_us&edition=fundamental","pubTime":"2025-10-09 00:15","pubTimestamp":1759940115,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on CervoMed today and set a price target of $20.00. Soumit Roy has given his Buy rating due...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-in-clinical-trials-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-in-clinical-trials-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2573295139","title":"CervoMed Inc Shares Rise 3.5% After Dementia Drug Shows Promise in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573295139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573295139?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:31","pubTimestamp":1759930289,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2573926683","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66","url":"https://stock-news.laohu8.com/highlight/detail?id=2573926683","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573926683?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:09","pubTimestamp":1759928989,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL6N3VP0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSX","NVDD","AU","NVDS.UK","NVD2.UK","NVDU","LU0466842654.USD","3NVD.UK","NVDX","EVR","LU2456880835.USD","LU1941712264.USD","LU0128526141.USD","NEM","SG9999015358.SGD","HOTH","NVD3.UK","HL","2NVD.UK","LU0345768740.USD","NVDY","ZBIO","ESPR","LYV","CFLT","NVDS","CVS","FDX","NVD","FRPT","VZ","IE00BHPRN162.USD","NVIW.SI","CRVO","HOWL","LU0788109121.HKD","CDE","F","LU0061474705.USD","WERN","SLB","SNVD.UK"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":69,"code":"91000000","status":"200"}]}}